<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01029782</url>
  </required_header>
  <id_info>
    <org_study_id>KGHQEII-0001</org_study_id>
    <nct_id>NCT01029782</nct_id>
  </id_info>
  <brief_title>Comparison of Intravenous Cefazolin Plus Oral Probenecid With Oral Cephalexin for the Treatment of Cellulitis</brief_title>
  <official_title>Intravenous Cefazolin Plus Oral Probenecid vs. Oral Cephalexin for the Treatment of Cellulitis: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kelowna General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Society of Hospital Pharmacists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Capital Health, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Interior Health Authority, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kelowna General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether oral cephalexin is equivalent to
      intravenous cefazolin plus oral probenecid for the treatment of uncomplicated skin and soft
      tissue infections in patients that present to the emergency department.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Skin and soft tissue infections (SSTIs) are a common reason for presentation to an Emergency
      Department (ED) in Canada. Although many patients with mild SSTI are able to be managed at
      home with oral antibiotics, those with mild-moderate infections are often treated with
      parenteral antibiotics. Current practice patterns in Canadian EDs indicate this patient
      population is often treated with intravenous cefazolin once daily along with oral probenecid
      and return to the ED or other ambulatory setting for daily medication administration and
      assessment. This parenteral regimen has been found to result in success rates comparable to
      studies which have evaluated treatment success with oral antibiotics in this patient
      population (89-97%). Although successful outcome can be achieved with this approach, it is
      often inconvenient for the patient to return to the ED/ambulatory care unit daily and does
      contribute to overall ED/ambulatory care visit volumes and overall health care costs.
      Unfortunately, there has never been a study which has evaluated the relative efficacy and
      safety or oral antibiotics to the aforementioned parenteral approach in this patient
      population and thus there remains a significant knowledge gap which must be addressed before
      a change in current practice can be explored.

      The objective of the study is to determine whether oral cephalexin is equivalent to
      intravenous cefazolin plus oral probenecid for the treatment of uncomplicated SSTIs in
      patients that present to the ED. This study will be a prospective, multi-centered, randomized
      controlled non-inferiority trial comparing cephalexin 500 mg orally four times to cefazolin 2
      g IV plus probenecid 1 g orally, in patients presenting to the ED with presumed diagnosis of
      SSTI. The primary outcome will be to compare the proportion of patients failing therapy for
      their cellulitis after 72 hours of antibiotic treatment with oral cephalexin or IV
      cefazolin/oral probenecid 1 g daily. Secondary outcomes include the clinical cure rate at 7
      days, percentage of patients requiring hospital admission, percentage of patients stepped
      down to oral antibiotics on or before day 7 of therapy, percentage of patients requiring an
      additional antibiotic prescription on day 7, and the frequency of adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Patients Failing Therapy After 72 Hours of Antibiotic Treatment With Oral Cephalexin or Intravenous Cefazolin Plus Oral Probenecid.</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">206</enrollment>
  <condition>Cellulitis</condition>
  <arm_group>
    <arm_group_label>IV cefazolin plus oral probenecid and placebo cephalexin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral cephalexin and saline IV plus probenecid placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV cefazolin plus oral probenecid and placebo cephalexin</intervention_name>
    <description>Intravenous cefazolin 2 g IV plus probenecid 1 g daily plus cephalexin placebo orally four times daily.</description>
    <arm_group_label>IV cefazolin plus oral probenecid and placebo cephalexin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral cephalexin and saline IV plus probenecid placebo</intervention_name>
    <description>Cephalexin 500 mg orally four times daily plus saline IV and oral probenecid placebo daily</description>
    <arm_group_label>Oral cephalexin and saline IV plus probenecid placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients presenting to the emergency department with a presumed diagnosis of mild to
             moderate skin and soft tissue infection

          -  Deemed well enough to be treated as an outpatient

          -  19 years of age or older

        Exclusion Criteria:

          -  known allergy to study drugs

          -  known chronic kidney disease with a creatinine clearance &lt;30 mL/min

          -  known previous methicillin-resistant staphylococcus aureus (MRSA) infection

          -  use of antibiotics for greater than 24 hours in the past 7 days

          -  wound/abscess requiring operative debridement or incision and drainage

          -  suspected necrotizing fasciitis, osteomyelitis or septic arthritis

          -  febrile neutropenia

          -  concomitant documented bacteremia

          -  Two or more signs of systemic sepsis

          -  new altered mental status

          -  infections at a site involving prosthetic materials

          -  animal or human bite wound infections

          -  post-operative wound infections

          -  known peripheral vascular disease

          -  superficial thrombophlebitis

          -  pregnant/breastfeeding

          -  obesity (BMI &gt; 30 kg/m2)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dawn Dalen, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Interior Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Zed, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Capital Health, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kelowna General Hospital</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 1T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>December 9, 2009</study_first_submitted>
  <study_first_submitted_qc>December 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2009</study_first_posted>
  <results_first_submitted>October 6, 2017</results_first_submitted>
  <results_first_submitted_qc>August 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2018</results_first_posted>
  <last_update_submitted>August 10, 2018</last_update_submitted>
  <last_update_submitted_qc>August 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kelowna General Hospital</investigator_affiliation>
    <investigator_full_name>Dawn Dalen</investigator_full_name>
    <investigator_title>Clinical Pharmacy Specialist, Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>Cellulitis</keyword>
  <keyword>Emergency Department</keyword>
  <keyword>Cefazolin</keyword>
  <keyword>Probenecid</keyword>
  <keyword>Cephalexin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cellulitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Cephalexin</mesh_term>
    <mesh_term>Probenecid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were included if they presented to the ED with presumed diagnosis of mild-moderate SSTI and were deemed well enough to be treated as outpatients and be able to return to the ED daily.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin</title>
          <description>IV cefazolin plus oral probenecid and placebo cephalexin: Intravenous cefazolin 2 g IV plus probenecid 1 g daily plus cephalexin placebo orally four times daily.</description>
        </group>
        <group group_id="P2">
          <title>Oral Cephalexin and Saline IV Plus Probenecid Placebo</title>
          <description>Oral cephalexin and saline IV plus probenecid placebo: Cephalexin 500 mg orally four times daily plus saline IV and oral probenecid placebo daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Diagnosis changed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Three patients in the cephalexin arm were removed, as 2 had exclusion criteria found prior to the first doses of study medication were given and 1 patient withdrew consent in the first 24 hours.</population>
      <group_list>
        <group group_id="B1">
          <title>IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin</title>
          <description>IV cefazolin plus oral probenecid and placebo cephalexin: Intravenous cefazolin 2 g IV plus probenecid 1 g daily plus cephalexin placebo orally four times daily.</description>
        </group>
        <group group_id="B2">
          <title>Oral Cephalexin and Saline IV Plus Probenecid Placebo</title>
          <description>Oral cephalexin and saline IV plus probenecid placebo: Cephalexin 500 mg orally four times daily plus saline IV and oral probenecid placebo daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
            <count group_id="B2" value="101"/>
            <count group_id="B3" value="203"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="102"/>
                    <count group_id="B2" value="101"/>
                    <count group_id="B3" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.21" spread="17.71"/>
                    <measurement group_id="B2" value="52.01" spread="19.64"/>
                    <measurement group_id="B3" value="53.62" spread="18.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="102"/>
                    <count group_id="B2" value="101"/>
                    <count group_id="B3" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="102"/>
                    <count group_id="B2" value="101"/>
                    <count group_id="B3" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Patients Failing Therapy After 72 Hours of Antibiotic Treatment With Oral Cephalexin or Intravenous Cefazolin Plus Oral Probenecid.</title>
        <time_frame>72 hours</time_frame>
        <population>Per-Protocol Analysis at 72 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin</title>
            <description>IV cefazolin plus oral probenecid and placebo cephalexin: Intravenous cefazolin 2 g IV plus probenecid 1 g daily plus cephalexin placebo orally four times daily.</description>
          </group>
          <group group_id="O2">
            <title>Oral Cephalexin and Saline IV Plus Probenecid Placebo</title>
            <description>Oral cephalexin and saline IV plus probenecid placebo: Cephalexin 500 mg orally four times daily plus saline IV and oral probenecid placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients Failing Therapy After 72 Hours of Antibiotic Treatment With Oral Cephalexin or Intravenous Cefazolin Plus Oral Probenecid.</title>
          <population>Per-Protocol Analysis at 72 hours.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin</title>
          <description>IV cefazolin plus oral probenecid and placebo cephalexin: Intravenous cefazolin 2 g IV plus probenecid 1 g daily plus cephalexin placebo orally four times daily.</description>
        </group>
        <group group_id="E2">
          <title>Oral Cephalexin and Saline IV Plus Probenecid Placebo</title>
          <description>Oral cephalexin and saline IV plus probenecid placebo: Cephalexin 500 mg orally four times daily plus saline IV and oral probenecid placebo daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Vomit</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dawn Dalen</name_or_title>
      <organization>Interior Health</organization>
      <phone>250-862-4449</phone>
      <email>dawn.dalen@interiorhealth.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

